| Metric | This Period | Prior Year Period | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥852.8B | ¥773.4B | +10.3% |
| Operating Income / Operating Profit | ¥37.0B | ¥26.3B | +40.7% |
| Ordinary Income | ¥49.6B | ¥36.6B | +35.5% |
| Net Income / Net Profit | ¥36.0B | ¥24.7B | +46.1% |
| ROE | 1.3% | 0.9% | - |
FY2026 Q1 results showed a strong start with Revenue ¥852.8B (vs prior year +¥79.4B +10.3%), Operating Income ¥37.0B (vs prior year +¥10.7B +40.7%), Ordinary Income ¥49.6B (vs prior year +¥13.0B +35.5%), and Net Income ¥36.0B (vs prior year +¥11.4B +46.1%), representing growth in both sales and profit. Operating margin improved to 4.3% (up +1.7pt from 2.6% prior year), and net margin improved to 4.2% (up +1.0pt from 3.2% prior year), indicating enhanced profitability. High-margin growth in Overseas operations (Revenue +26.9%, Operating Income +46.7%) drove consolidated performance, while domestic Dairy Food (Operating loss ¥23.1B) and Health and Food (Operating loss ¥12.9B) continued to post losses, remaining structural challenges. Non-operating items included Investment Partnership gains ¥10.0B, and Extraordinary gains included gains on sales of investment securities ¥4.6B, which boosted Net Income.
[Revenue] Revenue reached ¥852.8B (+10.3%), achieving double-digit growth. By segment, Overseas ¥264.5B (+26.9%, composition 31.0%) was the largest growth driver, accounting for approximately ¥66.6B of the revenue increase. Domestically, Nutritional Confectionery ¥154.5B (+2.6%, composition 18.1%), Dairy Food ¥142.0B (+2.9%, composition 16.6%), Health and Food ¥88.9B (+6.1%, composition 10.4%), and Other Domestic ¥192.5B (+3.0%, composition 22.6%) all recorded revenue increases, while Food Ingredients ¥28.5B (-2.4%, composition 3.3%) was the only segment with revenue decline. Brand penetration, channel expansion, and favorable FX supported Overseas revenue growth.
[Profitability] Gross profit was ¥320.5B (gross margin 37.6%, down -1.1pt from 38.7% prior year), and SG&A was ¥283.5B (SG&A ratio 33.2%, improved -2.1pt from 35.3% prior year). While higher raw material and packaging costs pressured gross profit, SG&A control was effective, resulting in Operating Income ¥37.0B (Operating margin 4.3%, +1.7pt improvement) — a substantial increase. By segment, Overseas Operating Income ¥48.1B (margin 18.2%) contributed roughly 130% of consolidated Operating Income, the largest contributor. Conversely, Dairy Food recorded an Operating loss of ¥23.1B (margin -16.2%), and Health and Food an Operating loss of ¥12.9B (margin -14.5%), diluting profits. Nutritional Confectionery had Operating Income ¥7.9B (margin 5.1%, -30.0%), a decline, while Food Ingredients earned ¥4.9B (margin 17.2%, +20.4%), an increase. Non-operating income comprised interest income ¥1.6B, equity-method gains ¥2.8B, and Investment Partnership gains ¥10.0B — totaling non-operating income ¥19.1B, against non-operating expenses ¥6.5B (including FX losses ¥6.0B), resulting in Ordinary Income ¥49.6B (+35.5%). Extraordinary gains were ¥5.0B (of which gains on sales of investment securities ¥4.6B), producing Profit Before Tax ¥54.6B. After deducting income taxes ¥18.6B and non-controlling interests ¥0.2B, Net Income was ¥36.0B (+46.1%). In conclusion, high-margin Overseas growth and SG&A efficiencies drove the increase in both revenue and profit.
Overseas: Revenue ¥264.5B (+26.9%), Operating Income ¥48.1B (+46.7%, margin 18.2%) — the largest contributor to consolidated profit. High-margin overseas expansion was effective, with Operating Income up ¥15.3B year-on-year, exceeding consolidated profit growth. Dairy Food: Revenue ¥142.0B (+2.9%), Operating loss ¥23.1B (vs prior year -1.1%, margin -16.2%) — losses continue. Despite slight top-line growth, cost and fixed-cost absorption have not progressed, and profitability has not recovered. Health and Food: Revenue ¥88.9B (+6.1%), Operating loss ¥12.9B (vs prior year +0.2%, margin -14.5%) — losses essentially flat. Delays in product mix improvement and investment burden weigh on results. Nutritional Confectionery: Revenue ¥154.5B (+2.6%), Operating Income ¥7.9B (-30.0%, margin 5.1%) — a decline in profit. Rising costs reduced margins versus prior year. Food Ingredients: Revenue ¥28.5B (-2.4%), Operating Income ¥4.9B (+20.4%, margin 17.2%) — maintained high profitability. Despite revenue decline, efficiency gains secured profit growth. Other Domestic: Revenue ¥192.5B (+3.0%), Operating Income -¥0.0B (-100.8%) — nearly break-even but worsened year-on-year.
[Profitability] Operating margin 4.3% (improved +1.7pt from 2.6% prior year), Net margin 4.2% (improved +1.0pt from 3.2% prior year) — profitability is trending upward. However, an EBIT margin of 4.3% remains low within the food industry, making correction of domestic loss-making segments pivotal. ROE is 1.3% (comparison to prior year period unclear), explained by Net margin × Total asset turnover 0.22 × Financial leverage 1.39x. [Cash Quality] Accounts receivable ¥396.3B (vs prior year ¥504.8B, -21.5%) declined significantly, indicating improved collections, while Inventories ¥228.7B (vs prior year ¥212.4B, +7.6%) increased. Accounts payable ¥304.6B (vs prior year ¥442.7B, -31.2%) fell markedly, suggesting shortened payment terms. Working capital efficiency still has room for improvement in inventory turnover days and receivables management. [Investment Efficiency] Total assets ¥3,838.3B (vs prior year ¥3,941.3B, -2.6%), with total asset turnover 0.22x indicating low asset efficiency. Tangible fixed assets ¥1,039.1B and investment securities ¥586.3B are held, reflecting a relatively conservative asset mix. [Financial Soundness] Equity Ratio 72.2% (improved +1.7pt from 70.5% prior year), Interest-bearing debt ¥121.5B (vs prior year ¥1.5B, a large increase), and Cash and Deposits ¥671.1B maintain a net cash position. Current ratio 195.4% and quick ratio 169.1% indicate ample liquidity. Short-term borrowings ¥120.4B increased sharply from ¥0.5B prior year but can be sufficiently covered by cash and investment securities.
Although the cash flow statement is not disclosed, balance sheet movements indicate that Cash and Deposits are ¥671.1B (vs prior year ¥686.3B, down ¥15.2B). Accounts receivable decreased by ¥108.5B, indicating improved collections, while Inventories increased ¥16.2B, reflecting inventory investment, and Accounts payable decreased ¥138.1B, suggesting accelerated payments that pressured working capital. Short-term borrowings increased ¥120.0B, likely to meet working capital needs and settle accounts payable. Investment securities increased to ¥586.3B (vs prior year ¥558.2B, +¥28.1B), and gains on sales of investment securities ¥4.6B were recorded, indicating portfolio rotation. Fixed assets were largely unchanged, with no large-scale investments identified. The structure appears to finance part of operating profits through working capital and short-term borrowings while leveraging investment securities income and sales. Going forward, improving inventory turnover and re-optimizing accounts payable terms are key to enhancing operating cash generation.
Of current period Net Income ¥36.0B, Operating Income ¥37.0B represents recurring core earnings, and Non-operating income ¥19.1B includes Investment Partnership gains ¥10.0B and subsidy income ¥8.5B, which are volatile items. Equity-method earnings ¥2.8B are relatively stable, but Investment Partnership gains are market-dependent with limited repeatability. Extraordinary gains ¥5.0B (mainly gains on sales of investment securities ¥4.6B) are one-off boosts; the portion of Net Income attributable to extraordinary items is significant. Non-operating income as a percentage of Revenue is 2.2% (¥19.1B ÷ ¥852.8B), below 5% and within an acceptable range, yet non-operating contributions are not negligible. The effective tax rate is approximately 34.0% (Income before tax ¥54.6B vs income taxes ¥18.6B), which is standard and does not introduce significant tax-driven distortions. In conclusion, core operating profit growth is commendable, but the Net Income progress rate of 35.8% (vs Full Year forecast ¥100.0B) includes contributions from non-operating and extraordinary items, implying normalization is expected over the full year.
Full Year guidance: Revenue ¥3,800.0B (vs prior year +5.1%), Operating Income ¥140.0B (vs prior year +60.2%), Ordinary Income ¥170.0B (vs prior year +46.0%), Net Income ¥100.0B (Forecast EPS ¥157.08). Q1 progress rates are: Revenue 22.4%, Operating Income 26.4%, Ordinary Income 29.2%, Net Income 36.0%. Operating Income and Ordinary Income slightly exceed standard progress (25%), and Net Income is more than 10pt ahead. The Net Income advance is mainly due to gains on sales of investment securities ¥4.6B and Investment Partnership gains ¥10.0B; therefore, assume normalization over the full year as non-recurring items fade. High-margin Overseas growth and SG&A efficiency drove the Operating Income outperformance; if domestic loss-making segments improve, there is upside to guidance. Dividend forecast maintained at annual ¥45, with expected Payout Ratio approximately 28.7%, a conservative stance. No revisions to earnings or dividend forecasts were made this quarter; the start is assessed as on track to meet guidance.
Annual dividend forecast ¥45 (unchanged from prior year ¥45). Payout Ratio relative to Forecast EPS ¥157.08 is approximately 28.7%, a conservative level. Based on outstanding shares 68,469 thousand less treasury shares 5,323 thousand, annual total dividends amount to approximately ¥2,840M. With Cash and Deposits ¥671.1B, a net cash position, and a trend of Operating Income growth, dividend sustainability is high and future dividend increases are possible. No share buybacks have been disclosed; shareholder returns are concentrated on dividends. Assessment of dividend yield and Total Return Ratio requires share price data, but the payout ratio indicates a stable return policy.
Raw material and packaging cost volatility risk: Gross margin fell -1.1pt year-on-year to 37.6%, driven by increases in raw materials, energy, and packaging costs. Continued upward pressure on procurement costs, coupled with delayed price pass-through, could slow improvements in operating margin. While high-margin Overseas operations can offset consolidated profits, sustained domestic gross margin declines would limit profit preservation through SG&A restraint alone.
Fixed-cost burden from domestic loss-making segments: Dairy Food Operating loss ¥23.1B and Health and Food Operating loss ¥12.9B total ¥36.0B, nearly equal to consolidated Operating Income ¥37.0B, offsetting Overseas high profitability. Delays in product portfolio review, production-site optimization, and demand forecasting improvements could prolong fixed-cost inefficiencies and prevent operating leverage from functioning, posing a long-term risk.
Deterioration in working capital efficiency: Accounts payable decreased ¥138.1B year-on-year while Inventories increased ¥16.2B, expanding working capital. Short-term borrowings of ¥120.0B were raised to supplement funding, but prolongation of inventory days and receivable collection days would reduce operating cash flow generation, constraining investment capacity and shareholder returns. Failure to improve DSO, DIO, and CCC could perpetuate low capital efficiency and lead to valuation discounts.
Profitability & Return
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 4.3% | – | – |
| Net Margin | 4.2% | – | – |
While the company’s Operating margin 4.3% and Net margin 4.2% improved year-on-year, median industry data is required for absolute-level comparison.
Growth & Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 10.3% | – | – |
Revenue growth rate 10.3% accelerated driven by Overseas operations and is estimated to be favorable in the industry relative position.
※ Source: Company compilation
Operating margin improved +1.7pt due to high-margin Overseas growth and SG&A efficiencies; Q1 Operating Income progress 26.4% exceeded standard progress. Overseas segment Operating margin 18.2% (sales composition 31.0%) is becoming a structural driver of consolidated profitability, and further overseas expansion and local brand penetration are expected to remain the main engine of profit growth. Conversely, domestic Dairy Food and Health and Food posted combined losses of ¥36.0B, nearly offsetting consolidated Operating Income ¥37.0B, indicating a structural issue. Portfolio review and production efficiency improvements could significantly enhance operating leverage.
Net Income progress 36.0% (vs Full Year forecast ¥100.0B) was supported by non-recurring items — gains on sales of investment securities ¥4.6B and Investment Partnership gains ¥10.0B — and normalization is expected over the full year. Core operating profit growth is solid, but volatility in non-operating and extraordinary items expands Net Income variability. Financial foundation is very strong with Equity Ratio 72.2%, net cash position, and Current Ratio 195.4%, indicating high resilience to external shocks. With a conservative payout ratio of 28.7%, there is potential for future dividend increases if profit growth and working capital efficiency improve. The sharp rise in short-term borrowings and large decrease in accounts payable indicate changes in working capital management; thus, improvements in inventory turnover and receivables collection will be catalysts for re-rating.
This report is an AI-generated earnings analysis document produced by analyzing XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the company based on publicly available financial statements. Investment decisions are your own responsibility; consult a professional advisor as needed before making any investment decisions.
---End of Report---